692 related articles for article (PubMed ID: 33779300)
1. Slow Coronary Flow: Pathophysiology, Clinical Implications, and Therapeutic Management.
Chalikias G; Tziakas D
Angiology; 2021 Oct; 72(9):808-818. PubMed ID: 33779300
[TBL] [Abstract][Full Text] [Related]
2. The Spontaneous Coronary Slow-Flow Phenomenon: Reversal by Intracoronary Nicardipine.
Mehta HH; Morris M; Fischman DL; Finley JJ; Ruggiero N; Walinsky P; McCarey M; Savage MP
J Invasive Cardiol; 2019 Mar; 31(3):42-45. PubMed ID: 30555052
[TBL] [Abstract][Full Text] [Related]
3. Risk factors and angiographic profile of coronary slow flow (CSF) phenomenon in North Indian population: An observational study.
Mukhopadhyay S; Kumar M; Yusuf J; Gupta VK; Tyagi S
Indian Heart J; 2018; 70(3):405-409. PubMed ID: 29961458
[TBL] [Abstract][Full Text] [Related]
4. Regional functions of the left ventricle in patients with coronary slow flow and the effects of nebivolol.
Gunes Y; Tuncer M; Guntekin U; Ceylan Y; Sahin M; Simsek H
Ther Adv Cardiovasc Dis; 2009 Dec; 3(6):441-6. PubMed ID: 19734185
[TBL] [Abstract][Full Text] [Related]
5. A randomized, single-center double-blinded trial on the effects of diltiazem sustained-release capsules in patients with coronary slow flow phenomenon at 6-month follow-up.
Li L; Gu Y; Liu T; Bai Y; Hou L; Cheng Z; Hu L; Gao B
PLoS One; 2012; 7(6):e38851. PubMed ID: 22761709
[TBL] [Abstract][Full Text] [Related]
6. Opium addiction as an independent risk factor for coronary microvascular dysfunction: A case-control study of 250 consecutive patients with slow-flow angina.
Esmaeili Nadimi A; Pour Amiri F; Sheikh Fathollahi M; Hassanshahi G; Ahmadi Z; Sayadi AR
Int J Cardiol; 2016 Sep; 219():301-7. PubMed ID: 27343424
[TBL] [Abstract][Full Text] [Related]
7. Effect of Shexiang Tongxin Dropping Pills () on the Immediate Blood Flow of Patients with Coronary Slow Flow.
Wang SH; Chu L; Xu Z; Zhou HL; Chen JF; Ning HF
Chin J Integr Med; 2019 May; 25(5):360-365. PubMed ID: 29915906
[TBL] [Abstract][Full Text] [Related]
8. Association between impaired cutaneous microvascular endothelial function and lectin-like oxidized low-density lipoprotein receptor-1 in patients with coronary slow flow.
Zhao J; Zhang Y; Huang Z; Wu F; Li N; Liang C
Microvasc Res; 2020 May; 129():103984. PubMed ID: 31954703
[TBL] [Abstract][Full Text] [Related]
9. The no-reflow phenomenon in the coronary circulation.
Kiernan TJ; Ruggiero NJ; Bernal JM; Don CW; Witzke C; Kiernan GD; Cubeddu RJ; Yan BP
Cardiovasc Hematol Agents Med Chem; 2009 Jul; 7(3):181-92. PubMed ID: 19689256
[TBL] [Abstract][Full Text] [Related]
10. Coronary slow flow and acute coronary syndrome in a patient with spinal cord injury.
Aktoz M; Tatli E; Barutcu A; Ozkalayci F; Umit E; Altun A
Tex Heart Inst J; 2011; 38(4):433-6. PubMed ID: 21841878
[TBL] [Abstract][Full Text] [Related]
11. Aortic pressures, stiffness and left ventricular function in coronary slow flow phenomenon.
Tanriverdi H; Evrengul H; Kilic ID; Taskoylu O; Dogan G; Alpsoy S
Cardiology; 2010; 116(4):261-7. PubMed ID: 20798537
[TBL] [Abstract][Full Text] [Related]
12. Dipyridamole versus verapamil for treatment of no-reflow during primary angioplasty.
Tanzilli G; Greco C; Pasceri V; Pelliccia F; Arrivi A; Placanica A; Mangieri E
Catheter Cardiovasc Interv; 2010 Nov; 76(6):787-93. PubMed ID: 20737584
[TBL] [Abstract][Full Text] [Related]
13. The effect of trimetazidine on ventricular repolarization indexes and left ventricular diastolic function in patients with coronary slow flow.
Suner A; Cetin M
Coron Artery Dis; 2016 Aug; 27(5):398-404. PubMed ID: 27140844
[TBL] [Abstract][Full Text] [Related]
14. The presence of fragmented QRS on 12-lead ECG in patients with coronary slow flow.
Yilmaz H; Gungor B; Kemaloglu T; Sayar N; Erer B; Yilmaz M; Cakmak N; Gurkan U; Oz D; Bolca O
Kardiol Pol; 2014; 72(1):14-9. PubMed ID: 24469747
[TBL] [Abstract][Full Text] [Related]
15. Effect of intracoronary agents on the no-reflow phenomenon during primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction: a network meta-analysis.
Niu X; Zhang J; Bai M; Peng Y; Sun S; Zhang Z
BMC Cardiovasc Disord; 2018 Jan; 18(1):3. PubMed ID: 29320987
[TBL] [Abstract][Full Text] [Related]
16. Intracoronary injection of drugs to treat no--reflow phenomenon and microcirculatory dysfunction.
Rognoni A; Lupi A; Cavallino C; Secco GG; Rosso R; Bongo AS
Cardiovasc Hematol Agents Med Chem; 2013 Jun; 11(2):84-8. PubMed ID: 22973862
[TBL] [Abstract][Full Text] [Related]
17. Incidence and outcomes of no-reflow phenomenon during percutaneous coronary intervention among patients with acute myocardial infarction.
Harrison RW; Aggarwal A; Ou FS; Klein LW; Rumsfeld JS; Roe MT; Wang TY;
Am J Cardiol; 2013 Jan; 111(2):178-84. PubMed ID: 23111142
[TBL] [Abstract][Full Text] [Related]
18. Clinical, demographic, risk factor and angiographic profile of coronary slow flow phenomenon: A single centre experience.
Sanghvi S; Mathur R; Baroopal A; Kumar A
Indian Heart J; 2018 Dec; 70 Suppl 3(Suppl 3):S290-S294. PubMed ID: 30595277
[TBL] [Abstract][Full Text] [Related]
19. The pathogenesis and treatment of no-reflow occurring during percutaneous coronary intervention.
Movahed MR; Butman SM
Cardiovasc Revasc Med; 2008; 9(1):56-61. PubMed ID: 18206640
[TBL] [Abstract][Full Text] [Related]
20. Effect of diltiazem on coronary flow reserve in patients with microvascular angina.
Sütsch G; Oechslin E; Mayer I; Hess OM
Int J Cardiol; 1995 Nov; 52(2):135-43. PubMed ID: 8749873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
